
FDA Releases Guidance on Osteoporosis Treatment
The agency published guidance on the nonclinical evaluation of osteoporosis treatments.
On June 13, 2016, FDA released
According to FDA, long-term nonclinical bone quality studies should be conducted for osteoporosis treatments because of concerns about long-term adverse effects of these drugs on bone quality and “because there are no validated and reliable methods for the noninvasive assessment of bone quality in humans.” The guidance addresses toxicology, bone quality, and biopharmaceutical nonclinical studies. Regulatory aspects and anabolic agents are also discussed.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.